Analyst Update: Altera, Eli Lilly and Co, and Vertex

Analysts adjusted their ratings on ALTR, LLY, and VRTX

Dec 11, 2014 at 1:37 PM
facebook twitter linkedin

Analysts are weighing in today on semiconductor firm Altera Corporation (NASDAQ:ALTR), as well as drug developers Eli Lilly and Co (NYSE:LLY) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Here's a quick look at today's brokerage notes on ALTR, LLY, and VRTX.

  • ALTR is nearly 3% higher at $38.20, following a round of price-target hikes from no fewer than five brokerage firms. The most ambitious among them is courtesy of Raymond James, which lifted its target by $5 to $45, and reiterated a "strong buy" opinion. Earlier, in fact, shares of Altera Corporation hit an annual high of $38.34, and longer term, they're up 17.5% year-to-date. Options traders remain unconvinced, however. ALTR's 10-day put/call volume ratio at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) is a brow-raising 29.91, as nearly 30 puts have been bought to open for every call over the last two weeks. What's more, this number ranks just 1 percentage point shy of a 12-month high. However, a portion of these bearish positions may have been initiated by shareholders protecting against a pullback.

  • LLY has tacked on 3.1% to trade at $73.25, and earlier hit a fresh decade peak of $75.10, after Morgan Stanley upgraded the stock to "overweight" from "underweight," and boosted its price target to $85 from $60. On the charts, the shares have put on a show, advancing nearly 44% in 2014, ushered higher by their ascending 20-week moving average. That said, additional bullish brokerage notes could be forthcoming, potentially providing a tailwind. Three-fifths of covering analysts rate Eli Lilly and Co a "hold" or worse, and the stock's consensus 12-month price target of $68.16 represents a discount to current trading levels.

  • VRTX is benefiting from a massive price-target hike to $130 from $94 at Credit Suisse -- though the brokerage firm reiterated a tepid "neutral" opinion on the shares. Specifically, the stock has rallied almost 4% to trade at $121.78, and earlier touched an all-time high of $122.26. What's more, year-to-date, Vertex Pharmaceuticals Incorporated has gained roughly 64%. Not surprisingly, traders at the ISE, CBOE, and PHLX have been betting bullishly in recent weeks. VRTX's 10-day call/put volume ratio across these exchanges is 9.24, or in the 97th percentile of its annual range.

Now is the time to join our thriving community of Event Traders who consistently profit from every earnings season. With this discounted subscription opportunity, you'll stay ahead of the curve and seize opportunities others miss. Do not let Q3 earnings season pass you by – subscribe now and supercharge your portfolio with expert insights that turn market reactions into profit-generating opportunities!! Don't waste another second... join us right now before the next trade targeting +200% is released!